Daflon 500 mg/Daflon 1000 mg Mechanism of Action

Pharmacotherapeutic group: VASCULOPROTECTIVE/CAPILLARY STABILIZING AGENTS/BIOFLAVONOIDS (C05CA53: cardiovascular system).
Pharmacology: Pharmacodynamics: Daflon exerts an action on the vascular return system: at the venous level, it reduces venous distensibility and reduces venous stasis; at the microcirculatory level, it normalises capillary permeability and reinforces capillary resistance.
Clinical pharmacology: Controlled, double-blind studies using methods that allow demonstrating and quantifying the activity on venous haemodynamics have confirmed the pharmacological properties of this medicinal product in humans.
Dose/effect relationship: Statistically-significant dose-effect relationships have been demonstrated for the following venous physiopathology parameters: capacitance, distensibility and emptying time. The best dose/effect ratio is obtained with 2 tablets (for Daflon 500 mg)/1 tablet (for Daflon 1000 mg).
Venotonic activity: It increases venous tone: venous occlusion plethysmography with a mercury strain gauge revealed a reduction in venous emptying time.
Microcirculatory activity: Controlled, double-blind studies have demonstrated a statistically-significant difference between this medicinal product and placebo. In patients with signs of capillary fragility, it increases capillary resistance as measured by angiosterrometry.
Clinical studies: Controlled double-blind clinical studies versus placebo demonstrated the therapeutic activity of the medicinal product in phlebology, in the treatment of chronic venous insufficiency (functional and organic) of the lower limbs.
Pharmacokinetics: In humans, following oral administration of the medicinal product with carbon 14-labelled diosmin: excretion is essentially faecal and urinary excretion is on average 14% of the administered quantity; the elimination half-life is of 11 hours; the product is highly metabolised, this metabolism is revealed by the presence of different phenol acids in the urine.
Toxicology: Preclinical safety data: Preclinical data from conventional toxicology studies of repeated dose toxicity, genotoxicity and reproductive function did not reveal any particular risk to humans.